Compare BGSF & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | BEAT |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 63.5M |
| IPO Year | N/A | 2021 |
| Metric | BGSF | BEAT |
|---|---|---|
| Price | $4.46 | $2.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $6.75 |
| AVG Volume (30 Days) | 51.2K | ★ 30.8M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | ★ 44.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $263,687,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.60 | N/A |
| 52 Week Low | $2.91 | $0.54 |
| 52 Week High | $8.22 | $3.48 |
| Indicator | BGSF | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 74.82 |
| Support Level | $4.25 | $0.66 |
| Resistance Level | $4.66 | $2.82 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 66.66 | 75.67 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.